Investors have now had a chance to digest the information and potential future medical breakthroughs that were presented at the 59th annual American Society of Hematologists meeting over the weekend. 

The conference, which was estimated to be attended by 25,000 people, showcased the cutting edge of treatments for blood disorders. 

Hematology is the study of blood and abnormalities of the cells and proteins that comprise blood. The global market for these diseases is expected to grow from nearly $86.5 billion in 2015 to $124.3 billion in 2020, according to BCC Research.

To be sure, the drug companies clearly have noticed the trend.

The Food and Drug Administration has approved 11 different treatments for hematological disorders this year, according to CenterWatch, and eight of those treatments address cancers of the blood.

Here are how some of the conference presenters are performing on the market Wednesday:

UniQure N.V. (QURE) shares have risen since it presented positive trial data from its hemophilia treatment candidate. The stock was up 2.34% Wednesday morning.

Juno Therapeutics Inc. (JUNO) continued to fall Wednesday, extending its losses to nearly 12% after the company presented data showing that the efficacy of its treatment for aggressive lymphoma was not as strong in current trials as it was in previous trials.

Spark Therapeutics (ONCE) shares were recovering from a sharp selloff earlier in the week, rising 3.3% Wednesday morning. Leerink downgraded the stock to "market perform" while also cutting the company's price target to $49 from $97. 

Spark rival BioMarin (BMRN) was a direct beneficiary of Spark's fall, but the stock has since also followed its rival lower. The stock was down 0.13% Wednesday morning. 

Celgene Corp. (CELG) shares were down slightly following the company's presentation at the ASH meeting. The company reported that 94% of patients in its CAR T cell therapy trial achieved an objective response, 89% achieved a very good partial response, and 56% achieved a complete response. 

Bluebird (BLUE) received positive reviews from analysts following its presentation of data on a cancer treatment that uses a patient's immune T-cells and re-engineers them to better fight the disease. 

Amgen (AMGN) shares rose after it said that the final analysis of the late-stage trial data showed that its blood cancer treatment Kyprolis helped patients live longer. The drug reportedly reduced the risk of death by 21% and extended survival by nearly 8 months. Amgen shares were up 0.33% Wednesday. 

More of What's Trending on TheStreet:

More from Stocks

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says